Yaohai Bio Secures Over RMB 100 Million in Series B+ Financing to Accelerate Global CRDMO One-Stop Service Platform Development

VCBeat has learned that recently,Jiangsu Yaohai-Bio Pharmaceutical Co., Ltd. (hereinafter referred to as “Yaohai-Bio”) announced the successful completion of its Series B+ financing round, with total proceeds exceeding RMB 100 million.This round of financing was led by CICC Qide Fund, under CICC Capital, with follow-on investments from well-known institutional investors such as Qiandao Fund.The proceeds from this financing round will be primarily used for the construction and operation of Yaohai-Bio’s Beijing R&D Center, the upgrade of its CRO technology platform, and the expansion of its talent team. Additionally, the funds will support the advancement of Yaohai-Bio’s international business layout, accelerating the development of an integrated microbial expression system CRDMO service platform that meets global standards.

Yaohai-Bio, established in 2010, is a pharmaceutical contract service provider specializing in microbial expression systems. The company has built an industry-leading one-stop CRDMO (Contract Research, Development, and Manufacturing Organization) service platform, with business covering recombinant proteins/peptides, recombinant plasmids, nucleic acid drugs, nanobodies, and novel recombinant vaccines. Currently, Yaohai-Bio has assembled specialized teams for process development, quality research, and GMP contract manufacturing. Leveraging a comprehensive and compliant quality management system, the company has successfully delivered over 200 projects, spanning the entire lifecycle from early-stage research, IND-enabling studies and clinical trial applications, to GMP production of clinical samples and commercial manufacturing.

To date, Yaohai-Bio has established a 20,000 m² R&D and production base that is operating steadily. The facility includes five GMP-compliant microbial fermentation and purification lines, two formulation lines for different dosage forms, and a modern quality management center, with a total fermentation capacity of up to 7,500 L. Meanwhile, Yaohai-Bio has built a CRO service platform for mRNA and CircRNA therapeutics. Going forward, the company will continue to deepen its strategic layout to enhance its end-to-end CRDMO capabilities for nucleic acid drugs, thereby empowering their R&D and industrialization.

Mr. Wang Manchao, Founding Partner and Managing Director of Yaohai-Bio, stated, “The successful completion of this round of financing marks another important milestone in Yaohai-Bio’s new journey of rapid development.”We sincerely appreciate CICC Capital’s recognition and its role as the lead investor, and we thank all participating investment institutions for their support in this round of financing for Yaohai-Bio. Amid the current winter in biopharmaceutical capital markets, Yaohai-Bio has earned the trust of clients and investors thanks to its differentiated innovation strategy, extensive industrialization experience, outstanding project service capabilities, and robust compliance system. Moving forward, we will continue to strengthen our technological innovation capabilities, enhance and optimize our compliance service framework, and continually upgrade our CRDMO service offerings. Meanwhile, we will actively attract top talent and expand our market presence both domestically and internationally, leveraging our multi-dimensional technology platforms and global service standards to deliver more comprehensive and premium R&D and manufacturing services to clients worldwide.

Dr. Huang Xu, Managing Director of CICC Capitalstated: “In recent years, the market for traditional recombinant protein drugs has demonstrated strong performance, while the clinical and commercial value of novel therapeutic modalities—such as nanobodies, cell and gene therapies, and nucleic acid-based drugs—has been validated. Investment in these related fields continues to increase, with specialized service capabilities playing a pivotal role. As a leading domestic CRDMO provider specializing in microbial expression systems, Yaohai-Bio has established technology platforms for recombinant peptides/proteins, nanobodies, plasmids, and nucleic acid therapeutics, supported by an experienced team of technical professionals and a rigorous, reliable production quality system. We are delighted to witness the company’s rapid development since its inception and believe that the team will continue to guide the company toward steady progress and sustained industry leadership. As a fund focused on biopharmaceutical investments, we are pleased to participate in this round of financing for Yaohai-Bio. Moving forward, we will remain committed to monitoring and supporting Yaohai-Bio’s growth, thereby fully advancing the development of innovative medicines in China.””

Mr. Jiang Yu, Senior Investment Director of Qian Dao Groupstated: “Yaohai-Bio has been deeply engaged in microbial expression system CRDMO services for many years, with its business focused on recombinant proteins/peptides, nucleic acid drugs, nanobodies, and novel recombinant vaccines. These areas are also key investment priorities for Qiandao Group in the biopharmaceutical sector. The founding team of Yaohai-Bio is pragmatic and steady, offering comprehensive service capabilities, extensive project experience, a robust production and quality system, and leading-scale operations, which have earned widespread recognition from customers both domestically and internationally. We believe that under the leadership of its founding team, the company will seize industry development opportunities, achieve rapid business growth, and continue to lead the field.””

CICC Capital is the private equity investment fund platform of China International Capital Corporation Limited (“CICC”), managing CICC’s onshore and offshore private equity investment fund businesses. The funds under its management cover a wide range of categories, including RMB corporate equity investment funds, funds of funds (FOFs), real estate funds, infrastructure funds, and USD corporate equity investment funds. As of the end of 2021, CICC Capital had cumulative assets under management exceeding RMB 400 billion, supported by a professional investment management team of over 400 members, establishing itself as a leading comprehensive alternative asset investment management platform in China with international influence.

Qiandao Group was founded in 2011. Upholding the philosophy of “empowering finance with technology, serving industries through financial services, and contributing to the nation through industrial development,” the Group has deeply participated in China’s economic growth and industrial upgrading, striving to become a comprehensive holding group led by technological innovation and dedicated to serving the real economy. The Group’s subsidiaries include Qiandao Investment Fund Management Co., Ltd., which focuses on pharmaceuticals and medical technology, advanced manufacturing, and new energy, as well as China Xinxing Asset Management Co., Ltd., a subsidiary of a central state-owned enterprise undergoing mixed-ownership reform. These entities specialize in asset management and investment activities such as equity investment, industrial investment, and special opportunity investment.

Yaohai-Bio, established in 2010, is a professional CRDMO service provider specializing in microbial expression systems and a nationally recognized high-tech enterprise. The company focuses on areas such as recombinant proteins/peptides, nucleic acid drugs, gene therapy, nanobodies, and novel recombinant vaccines, striving to build an open, integrated R&D and production service platform encompassing CRO, CDMO, and MAH models. By continuously enhancing its R&D, manufacturing, quality management, and control service systems, and developing distinctive platform technologies, Yaohai-Bio leverages its comprehensive service capabilities, extensive project experience, and leading scale advantages to provide domestic and international pharmaceutical companies with full-lifecycle CRDMO services—from process development to commercial production. This supports the smooth advancement of clients’ new drug projects and continuously empowers the development of the biopharmaceutical industry.